Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 8/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913436 | 0.86 | HTR1B (0.46) | SLC6A4SLC6A2HTR1BHTR1DNR2E1 | |
| SCHEMBL6915137 | 0.85 | HTR1B (0.45) | SLC6A4SLC6A2KDM4EKMT2AHTR1B | |
| SCHEMBL6917478 | 0.84 | HTR1B (0.44) | SLC6A4SLC6A2KDM4EKMT2AHTR1B | |
| SCHEMBL7240315 | 0.81 | DYRK1A (0.31) | — | |
| SCHEMBL9477676 | 0.79 | MCHR1 (0.51) | SLC6A4SLC6A2KDM4EMEN1CYP1A2 | |
| SCHEMBL10588548 | 0.78 | HTR1B (0.44) | SLC6A4SLC6A2KDM4EMEN1CYP1A2 | |
| SCHEMBL9477167 | 0.76 | MCHR1 (0.54) | SLC6A4SLC6A2KDM4EMEN1CYP1A2 | |
| SCHEMBL11805995 | 0.76 | MCHR1 (0.32) | — | |
| SCHEMBL8540012 | 0.75 | SLC6A4 (0.47) | SLC6A4SLC6A2KDM4EMEN1CYP1A2 | |
| SCHEMBL6447354 | 0.75 | KDM4E (0.42) | SLC6A4SLC6A2KDM4EMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | SLC6A4 4531/4885SLC6A2 4660/4885KDM4E 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.